Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including astrocytes; strongest in esophageal apical cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly vesicle traffic | 1.00 |
Knock down and overexpress TPD52L1 in astrocytes; measure LRRK2 kinase activity (pT73-Rab10) and lysosome position and α-synuclein uptake and degradation, and dopamine neuron survival in co-culture.
- Cell type
- astrocytes
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- LRRK2 kinase activity (pT73-Rab10) and lysosome position
- Functional readout
- α-synuclein uptake and degradation, and dopamine neuron survival in co-culture
- Rule-out
- If neither arm moves LRRK2 kinase activity (pT73-Rab10) by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of TPD52L1 in iPSC-derived midbrain astrocytes; n = 3 differentiations; readouts: LRRK2 kinase activity (pT73-Rab10) and lysosome position; α-synuclein uptake and degradation, and dopamine neuron survival in co-culture. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- TPD52L1 in dopamine neurons, braak-0.26 (p 0.504) → +0.21 (p 0.581)receipt 13554
- TPD52L1 in astrocytes, braak-0.11 (p 0.787) → -0.33 (p 0.393)receipt 13553
Swarm cases
receipt 13554: TPD52L1 in dopamine neurons, braak
- power
- full sample -0.06 (p 0.814, n 18), 95% CI -0.51 to +0.42. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.06 (p 0.814, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.08 (p 0.767, n 18). could be the mix.
- skeptic
- leave-one-out range -0.22 to +0.03, sign flips 3; without severely affected donors -0.06 (p 0.814, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TPD52L1 in dopamine neurons.
case closed: nothing better to follow up.
receipt 13553: TPD52L1 in astrocytes, braak
- power
- full sample -0.14 (p 0.585, n 18), 95% CI -0.57 to +0.35. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.17 (p 0.498, n 18). does not hold up.
- composition
- astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.22 (p 0.384, n 18). could be the mix.
- skeptic
- leave-one-out range -0.28 to +0.00, sign flips 3; without severely affected donors -0.14 (p 0.585, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TPD52L1 in astrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts